Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen W Erickson

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Leukemia|April 25, 2021
Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemiaJulia W Bӧhm, Keith C S Sia, Connor Jones, et al.
European Journal of Human Genetics : EJHG|January 7, 2010
Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progressionAndrzej B Popławski, Michał Jankowski, Stephen W Erickson, et al.
Hemasphere|January 20, 2025
The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemiaBen Watts, Christopher M Smith, Kathryn Evans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2019
OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALLKathryn Evans, JianXin Duan, Tara Pritchard, et al.
Pharmacology & Therapeutics|November 7, 2024
Lessons learned from 20 years of preclinical testing in pediatric cancersMalcolm A Smith, Peter J Houghton, Richard B Lock, et al.
Leukemia|December 19, 2019
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemiaKlaartje Somers, Kathryn Evans, Leanna Cheung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2021
The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor ModelsNathan M Kendsersky, Jarrett Lindsay, E Anders Kolb, et al.
Molecular Cancer Therapeutics|March 21, 2022
Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in OsteosarcomaYifei Wang, Xiangjun Tian, Wendong Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2018
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor ModelsCaitlin D Lowery, Michele Dowless, Matthew Renschler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2026
PRECLINICAL ACTIVITY OF THE B7-H3- TARGETING ANTIBODY-DRUG CONJUGATE (ADC) VOBRAMITAMAB DUOCARMAZINE (VOBRA DUO) IN PEDIATRIC SOLID TUMORSEdward Favours, Haiying Tang, Peyton Wong, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Leukemia|April 25, 2021
Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemiaJulia W Bӧhm, Keith C S Sia, Connor Jones, et al.
European Journal of Human Genetics : EJHG|January 7, 2010
Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progressionAndrzej B Popławski, Michał Jankowski, Stephen W Erickson, et al.
Hemasphere|January 20, 2025
The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemiaBen Watts, Christopher M Smith, Kathryn Evans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2019
OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALLKathryn Evans, JianXin Duan, Tara Pritchard, et al.
Pharmacology & Therapeutics|November 7, 2024
Lessons learned from 20 years of preclinical testing in pediatric cancersMalcolm A Smith, Peter J Houghton, Richard B Lock, et al.
Leukemia|December 19, 2019
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemiaKlaartje Somers, Kathryn Evans, Leanna Cheung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2021
The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor ModelsNathan M Kendsersky, Jarrett Lindsay, E Anders Kolb, et al.
Molecular Cancer Therapeutics|March 21, 2022
Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in OsteosarcomaYifei Wang, Xiangjun Tian, Wendong Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2018
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor ModelsCaitlin D Lowery, Michele Dowless, Matthew Renschler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2026
PRECLINICAL ACTIVITY OF THE B7-H3- TARGETING ANTIBODY-DRUG CONJUGATE (ADC) VOBRAMITAMAB DUOCARMAZINE (VOBRA DUO) IN PEDIATRIC SOLID TUMORSEdward Favours, Haiying Tang, Peyton Wong, et al.
Pageof 7